Published in Cancer Res on October 01, 1999
Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis. Genes Dev (2004) 2.04
Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP-ribosylating toxins on translation elongation factor 2. Mol Cell Biol (2004) 1.76
Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet (2003) 1.53
White spot syndrome virus open reading frame 222 encodes a viral E3 ligase and mediates degradation of a host tumor suppressor via ubiquitination. J Virol (2006) 1.01
The biosynthesis and biological function of diphthamide. Crit Rev Biochem Mol Biol (2013) 0.92
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS One (2012) 0.91
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One (2012) 0.89
A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene. J Biol Chem (2013) 0.89
Silencing of diphthamide synthesis 3 (Dph3) reduces metastasis of murine melanoma. PLoS One (2012) 0.81
Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas. Br J Cancer (2001) 0.78
A diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells. Sci Rep (2015) 0.75
Influence of DPH1 and DPH5 Protein Variants on the Synthesis of Diphthamide, the Target of ADPRibosylating Toxins. Toxins (Basel) (2017) 0.75
OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia. Oncol Lett (2017) 0.75
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24
Ultrastructure of the yeast actin cytoskeleton and its association with the plasma membrane. J Cell Biol (1994) 5.14
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene (1998) 4.88
KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HP1 proteins: a potential role for Krüppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing. Mol Cell Biol (1999) 4.19
The impact of role models on medical students. J Gen Intern Med (1997) 3.99
A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature (1996) 3.79
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res (1995) 3.04
Women prefer hospital births. BMJ (1992) 2.88
Experiences in Hong Kong with the theory and practice of the albumin column method of sperm separation for sex selection. Hum Reprod (1998) 2.87
Mutation detection using a novel plant endonuclease. Nucleic Acids Res (1998) 2.78
Energy efficient medium access protocol for wireless medical body area sensor networks. IEEE Trans Biomed Circuits Syst (2008) 2.75
BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet (1996) 2.75
Reconstitution of the KRAB-KAP-1 repressor complex: a model system for defining the molecular anatomy of RING-B box-coiled-coil domain-mediated protein-protein interactions. J Mol Biol (2000) 2.65
A randomised prospective trial of intra-operative oesophageal Doppler-guided fluid administration in major gynaecological surgery. Anaesthesia (2013) 2.63
Solution structure of the PHD domain from the KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding domains. EMBO J (2001) 2.54
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Functional interchangeability of DNA replication genes in Salmonella typhimurium and Escherichia coli demonstrated by a general complementation procedure. Genetics (1984) 2.42
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer (1998) 2.27
The DAF-3 Smad protein antagonizes TGF-beta-related receptor signaling in the Caenorhabditis elegans dauer pathway. Genes Dev (1997) 2.26
Multiple shunt failures: an analysis of relevant factors. Childs Nerv Syst (1998) 2.25
Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med (1995) 2.17
Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst (1996) 2.17
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet (1999) 2.14
A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol (1988) 2.14
Using a birth cohort to study ageing: representativeness and response rates in the National Survey of Health and Development. Eur J Ageing (2013) 2.12
The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol (2000) 2.07
Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology (1999) 2.04
Arginine deiminase system and bacterial adaptation to acid environments. Appl Environ Microbiol (1987) 2.03
Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem (1998) 1.90
Induction of human interferon gene expression is associated with a nuclear factor that interacts with the NF-kappa B site of the human immunodeficiency virus enhancer. J Virol (1989) 1.90
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res (2001) 1.81
A comprehensive analysis of high school genetics standards: are states keeping pace with modern genetics? CBE Life Sci Educ (2011) 1.80
Minimal access approach to the management of large ovarian cysts. Surg Endosc (2006) 1.78
The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol (1999) 1.67
Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) (2000) 1.64
Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost (1994) 1.63
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
The association of obesity with infertility and related menstural abnormalities in women. Int J Obes (1979) 1.57
The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability. Nat Genet (1999) 1.56
Choreoathetosis after deep hypothermia without circulatory arrest. Ann Thorac Surg (1990) 1.51
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2001) 1.51
Preoperative concurrent 5-fluorouracil infusion, mitomycin C and pelvic radiation therapy in tethered and fixed rectal carcinoma. Int J Radiat Oncol Biol Phys (1993) 1.51
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res (2001) 1.51
Mutations in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates. J Infect Dis (1994) 1.50
Genetic contamination of Dahl SS/Jr rats. Impact on studies of salt-sensitive hypertension. Hypertension (1994) 1.48
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol (2003) 1.48
Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356. J Biol Chem (1997) 1.48
Use of transcranial Doppler ultrasound to predict outcome in patients with intracranial large-artery occlusive disease. Stroke (2000) 1.46
Outcome after temporary vascular occlusion for the management of renal trauma. J Urol (1994) 1.44
Ovarian cancer biology. Semin Oncol (1991) 1.40
Structure-function studies of the BTB/POZ transcriptional repression domain from the promyelocytic leukemia zinc finger oncoprotein. Cancer Res (1999) 1.40
FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene (2012) 1.39
Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells. J Biol Chem (1998) 1.38
Co-localization of the myelin-associated glycoprotein and the microfilament components, F-actin and spectrin, in Schwann cells of myelinated nerve fibres. J Neurocytol (1989) 1.37
Structure and expression of ferritin genes in a human promyelocytic cell line that differentiates in vitro. Mol Cell Biol (1986) 1.37
Cloning, sequencing and disruption of a gene from Streptomyces clavuligerus involved in clavulanic acid biosynthesis. Gene (1994) 1.36
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna) (1998) 1.35
Characterization of a DNA probe for detection of Mycobacterium tuberculosis complex in clinical samples by polymerase chain reaction. J Clin Microbiol (1992) 1.34
Cognitive impairment and functional outcome after stroke associated with small vessel disease. J Neurol Neurosurg Psychiatry (2004) 1.33
Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer (2000) 1.32
Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cbl and Gab1. J Biol Chem (1997) 1.30
ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci (2000) 1.30
Nucleotide sequence of a coleopteran-active toxin gene from a new isolate of Bacillus thuringiensis subsp. tolworthi. Nucleic Acids Res (1990) 1.27
Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein. Immunity (2001) 1.26
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics (2001) 1.23
Analysis of acidic oligosaccharides and glycopeptides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chem (1996) 1.23
The Gab1 protein is a docking site for multiple proteins involved in signaling by the B cell antigen receptor. J Biol Chem (1998) 1.22
An epizootic of cutaneous zygomycosis in cultured dwarf African clawed frogs (Hymenochirus curtipes) due to Basidiobolus ranarum. J Med Vet Mycol (1991) 1.22
Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res (1996) 1.21
Cloning and characterization of human colon glyoxalase-I. J Biol Chem (1993) 1.21
A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res (1996) 1.21
The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood (1998) 1.20
Immunosuppressive and immunostimulatory factors produced by malignant cells in vitro. Int J Cancer (1974) 1.20
Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer (1997) 1.19
Disorganization of cultured vascular endothelial cell monolayers by fibrinogen fragment D. Science (1985) 1.19
In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun (2000) 1.19
Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res (1995) 1.18
Quality assessment and data analysis for microRNA expression arrays. Nucleic Acids Res (2008) 1.17
A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis. J Biol Chem (1999) 1.17
Genetics and ovarian carcinoma. Semin Oncol (1998) 1.17
The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem (2001) 1.16
Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest (1996) 1.15
CEL I enzymatic mutation detection assay. Biotechniques (2000) 1.15
Reverse transcriptase-PCR analysis of bacterial rRNA for detection and characterization of bacterial species in arthritis synovial tissue. Infect Immun (2000) 1.15
Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet (1996) 1.14
"Molecular rulers" for calibrating phenotypic effects of telomere imbalance. J Med Genet (2002) 1.14
Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res (1994) 1.14
The proteolytic substructure of light meromyosin. Localization of a region responsible for the low ionic strength insolubility of myosin. J Biol Chem (1983) 1.12
The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds. Cancer Res (1997) 1.12
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res (1993) 1.11